


We Claim:

1. A compound of formula (I):



(I)


or a pharmaceutically acceptable salt or solvate thereof, wherein:

- 5 Ring Q is (C₆-C₁₀)aryl or (4-10)-membered heterocyclyl;

- R¹ is H, halo, (C₁-C₈)alkyl, (C₁-C₈)alkoxy, CN, CF₃, -O-CF₃, -O-SO₂-(C₁-C₈)alkyl, -O-SO₂-(CR¹¹R¹²)_i(C₆-C₁₀)aryl, -(CR¹¹R¹²)_i(C₃-C₁₀)cycloalkyl-(CR¹¹R¹²)_i, -(CR¹¹R¹²)_i(C₃-C₁₀)cycloalkyl-(CR¹¹R¹²)_i-O-, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl-(CR¹¹R¹²)_i, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl-(CR¹¹R¹²)_i-O-, -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl-(CR¹¹R¹²)_i, or
 10 -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl-(CR¹¹R¹²)_i-O-; wherein the ring carbon atoms of R¹ are optionally substituted by 1 to 3 R¹³ groups; and the ring nitrogen atoms of R¹ are optionally substituted by 1 to 3 (C₁-C₈)alkyl;

- R² is H, (C₁-C₈)alkyl, -(CR¹¹R¹²)_i(C₃-C₁₀)cycloalkyl, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl, or -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl; and wherein the carbon atoms of R² are optionally substituted by 1 to 3 R¹³ groups; and the ring nitrogen atoms of R² are optionally substituted by 1 to 3 (C₁-C₈)alkyl;

R³ is selected from the group consisting of:



Y is -(C=O)- or -SO₂-;

Yⁿ is NR¹⁰ or -O-;

p is 0, 1, or 2;

each q, r, and t are independently 0, 1, 2, 3, 4, or 5;

each n is independently 0, 1, 2, 3, or 4;

5 each k is independently 1, 2, or 3;


each m and s are independently 0, 1, 2, or 3;

each j is 0, 1, or 2;

Each R⁴ is -(CR¹¹R¹²)_n-, -(CR¹¹R¹²)_n-S-(CR¹¹R¹²)_n-, -(CR¹¹R¹²)_n-NR¹⁰-,
 -(CR¹¹R¹²)_n-NR¹⁰-(CR¹¹R¹²)_n-O-, -(CR¹¹R¹²)_n-O-(CR¹¹R¹²)_k-NR¹⁰-, -(CR¹¹R¹²)_n-O-(CR¹¹R¹²)_n-,
 10 -(CR¹¹R¹²)_n-O-(CR¹¹R¹²)_k-O-(CR¹¹R¹²)_n-, -(CR¹¹R¹²)_n-CR¹¹=CR¹²-(CR¹¹R¹²)_n-, or
 -CH=CH-(CR¹¹R¹²)_n-O-(CH₂)_n-;

Each R⁵ is a bond or -(CR¹¹R¹²)_m-Z-(CR¹¹R¹²)_s; wherein Z is -CR¹¹R¹²-, -O-, -NR^{10a}-,
 or -S(O)_j-;

Each R⁶ is -(C=O)-OH, -(C=O)-OM⁺, -(C=O)-(C₁-C₈)alkyl, -(C=O)-O-(C₁-C₈)alkyl, -
 15 (C=O)-NR¹⁰R¹¹, -(C=O)-NR¹⁰-SO₂-R¹¹, -SO₂-NH-R¹⁰, -NH-SO₂-R¹⁰, -(C=O)-NH-C≡N, or R⁶
 has a formula:



M⁺ is an alkali metal cation or an alkaline earth metal cation;

Each R⁷ and R⁸ is independently H, (C₁-C₈)alkyl, (C₁-C₈)alkoxy,
 20 -(CR¹¹R¹²)_i(C₃-C₁₀)cycloalkyl, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl-O-,
 -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl or -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl-O-;

Or R⁷ and R⁸ may optionally be taken together with the carbon to which they are
 attached to form a (C₃-C₁₀)cycloalkyl or a (3-10)-membered heterocyclyl;

Each of Ar¹, Ar², Ar³, and Ar⁴ represents (C₆-C₁₀)aryl or (5-10)-membered
 25 heterocyclyl; wherein the ring carbon atoms of each of Ar¹, Ar², Ar³, and Ar⁴ are optionally
 substituted by 1 to 3 R¹³ groups;

Ring A represents a 3, 4, 5, 6 or 7-membered ring optionally containing 1 to 4
 heteroatoms which may be the same or different and which are selected from -N(R^{10a})-, O,
 and S(O)_j, wherein j is 0, 1, or 2, with the proviso that the ring does not contain two adjacent
 30 O or S(O)_j atoms, and wherein the carbon atoms of the ring A moiety are optionally
 substituted by 1 to 3 R¹³ groups;

R⁹ is (C₁-C₈)alkyl, -(CR¹¹R¹²)_i(C₆-C₁₀)aryl or -(CR¹¹R¹²)_i(4-10)-membered heterocyclyl,
 wherein t is independently 0, 1, 2, 3, 4, or 5, wherein said R⁹ groups are substituted with 1 to
 3 groups independently selected from -(CR¹¹R¹²)_qNR¹⁰R¹¹, -(CR¹¹R¹²)_qNR¹⁰(C₁-C₆)alkanoyl,

$-(CR^{11}R^{12})_qO(CR^{11}R^{12})_nR^{10}$, and $-(CR^{11}R^{12})_qR^{10}$; and wherein the heterocyclyl, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{13} groups;

R^{9a} and R^{10} are independently H or (C_1-C_8) alkyl;

R^{11} and R^{12} are independently H, (C_1-C_8) alkyl, hydroxy, or (C_1-C_6) alkoxy;

5 R^{10a} is selected from H, (C_1-C_8) alkyl, $-(C=O)-R^{14}$, $-SO_2NR^{15}R^{16}$, or $-S(O)_j(C_1-C_6)$ alkyl;


Each R^{13} and R^{13a} are independently selected from the group consisting of halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, (C_1-C_6) alkoxy, (C_1-C_{10}) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, $-O-(CR^{11}R^{12})_kO-(CR^{11}R^{12})_n-$, $-(C=O)-R^{14}$, $-(C=O)-O-R^{15}$, $-O-(C=O)-R^{15}$, $-NR^{15}(C=O)-R^{16}$, $-NR^{15}(C=O)-O-R^{16}$, $-(C=O)-NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-NR^{15}OR^{16}$, $-SO_2NR^{15}R^{16}$, $-S(O)_j(C_1-C_6)$ alkyl, $-O-SO_2-R^{14}$, $-NR^{15}-SO_2-R^{16}$, $R^{15}-(CR^{11}R^{12})_i(C_6-C_{10})$ aryl, $-(CR^{11}R^{12})_i(4-10)$ -membered heterocyclyl, $-(CR^{11}R^{12})_q(C=O)(CR^{11}R^{12})_i(C_6-C_{10})$ aryl, $-(CR^{11}R^{12})_q(C=O)(CR^{11}R^{12})_i(4-10)$ -membered heterocyclyl, $-(CR^{11}R^{12})_iO(CR^{11}R^{12})_q(C_6-C_{10})$ aryl, $-(CR^{11}R^{12})_iO(CR^{11}R^{12})_q(4-10)$ -membered heterocyclyl, $-(CR^{11}R^{12})_qSO_2(CR^{11}R^{12})_i(C_6-C_{10})$ aryl, and $-(CR^{11}R^{12})_qSO_2(CR^{11}R^{12})_i(4-10)$ -membered heterocyclyl; 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{13} and R^{13a} groups are optionally substituted with an oxo ($=O$) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{13} and R^{13a} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^{15}$, $-(C=O)-R^{15}$, $-(C=O)-O-R^{15}$, $-O-(C=O)-R^{15}$, $-NR^{15}(C=O)-R^{16}$, $-(C=O)-NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-NR^{15}OR^{16}$, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, $-(CR^{11}R^{12})_i(C_6-C_{10})$ aryl, and $-(CR^{11}R^{12})_i(4-10)$ -membered heterocyclyl;

each R^{14} , R^{15} , and R^{16} is independently selected from H, (C_1-C_8) alkyl, $-(CR^{11}R^{12})_i(C_6-C_{10})$ aryl, and $-(CR^{11}R^{12})_i(4-10)$ -membered heterocyclyl; 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo ($=O$) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^{14} , R^{15} and R^{16} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^{11}R^{12}$, trifluoromethyl, trifluoromethoxy, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, hydroxy, and (C_1-C_6) alkoxy;


R^{17} is H, (C_1-C_8) alkyl, $-O-(C_1-C_8)$ alkyl, halo, CN, OH, CF_3 , or $-O-CF_3$;

30 and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group which is not attached to a halo, SO or SO_2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, halo, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, $-NH_2$, $-NH(C_1-C_8)$ alkyl, and $-N((C_1-C_8)alkyl)_2$.


2. The compound according to claim 1 wherein R^3 is



3. The compound according to claim 1 wherein R^3 is




4. The compound according to claim 1 wherein R^3 is




5

5. The compound according to claim 1 wherein R^3 is




6. The compound according to claim 1 wherein ring Q is selected from the group consisting of





7. The compound according to claim 1 wherein R^1 is H, halo, (C_1-C_8) alkyl, (C_1-C_8) alkoxy, CF_3 , $-O-CF_3$, $-O-SO_2-(C_1-C_8)$ alkyl, $-O-SO_2-(CR^{11}R^{12})_l(C_6-C_{10})$ aryl, or $-(CR^{11}R^{12})_l(C_6-C_{10})$ aryl-O-, wherein the ring carbon atoms of R^1 are optionally substituted by 1 to 3 R^{13} groups.


15


8. The compound according to claim 1 wherein R^2 is H, phenyl,








9. The compound according to claim 1 wherein said R^2  is selected from the group consisting of:




10. The compound according to claim 1 wherein said R^2  is selected from the group consisting of:



11. The compound according to claim 1 wherein said R^2  is selected from the group consisting of:




12. The compound according to claim 1 wherein R^4 is $\text{—CH}_2\text{—O—}$, $\text{—CH}_2\text{—O—CH}_2\text{—}$, $\text{—CH}_2\text{—CH}_2\text{—O—}$, $\text{—CH=CH—CH}_2\text{—O—}$, or $\text{—CH}_2\text{—CH}_2\text{—CH}_2\text{—O—}$.
13. The compound according to claim 1 wherein R^4 is $\text{—(CH}_2)_n\text{—}$; wherein n is independently 0, 1, 2, or 3.
14. The compound according to claim 1 wherein R^5 is a bond or $\text{—(CR}^{11}\text{R}^{12})_m\text{—Z—(CR}^{11}\text{R}^{12})_s\text{—}$; wherein Z is —O— , $\text{—NR}^{10a}\text{—}$, or $\text{—S(O)}_j\text{—}$; wherein each m and s are independently 0, 1, 2, or 3; and wherein j is 0, 1, or 2.
15. The compound according to claim 1 wherein R^5 is a bond, —O— , $\text{—CH}_2\text{—}$, $\text{—C(CH}_3)_2\text{—}$, —C(OH)H— , or $\text{—C(O—(C}_1\text{—C}_8\text{)alkyl)H—}$.
16. The compound according to claim 1 wherein R^6 is —(C=O)—OH .
17. The compound according to claim 1 wherein each R^7 and R^8 is independently H, $(\text{C}_1\text{—C}_8)\text{alkyl}$, or $(\text{C}_1\text{—C}_8)\text{alkoxy}$.
18. The compound according to claim 1 wherein each R^7 and R^8 are taken together with the carbon to which they are attached to form a (3-7)-membered heterocyclyl.
19. The compound according to claim 2 wherein said $\text{—Ar}^1\text{—Ar}^2\text{—}$ is selected from the group consisting of:



- 5 wherein the ring carbon atoms of each of Ar¹ and Ar² are optionally substituted by 1 to 3 R¹³ groups selected from the group consisting of halo, (C₁-C₈)alkyl, and (C₁-C₈)alkoxy.

20. The compound according to claim 2 wherein said -Ar¹-Ar²- is selected from the group consisting of:



- 10 21. The compound according to claim 2 selected from the group consisting of:
selected from the group consisting of

- 1-({3'-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1,1'-biphenyl-3-yl}oxy)cyclobutanecarboxylic acid (Example A-4);
2-({3'-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1,1'-biphenyl-3-yl}oxy)butanoic acid (Example A-5);
15 2-(3-{6-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}phenoxy)butanoic acid (Example A-6);
1-(3-{6-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}phenoxy)cyclobutanecarboxylic acid (Example A-7);
20 1-[(3'-{[2-(3-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}biphenyl-3-yl)oxy]cyclobutanecarboxylic acid (Example A-11);
1-({3'-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]biphenyl-3-yl}oxy)cyclobutanecarboxylic acid (Example A-12);
1-[(3'-{[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy}biphenyl-3-yl)oxy]cyclobutanecarboxylic acid (Example A-17);
25 2-[(3'-{2-[2-(3-Fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}biphenyl-3-yl)oxy]-2-methylpropanoic acid (Example A-21);
2-methyl-2-({3'-{[5-methyl-2-phenyl-1,3-oxazol-4-yl]methoxy}biphenyl-3-yl}oxy)propanoic acid (Example A-24);

2-ethoxy-3-{3'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]biphenyl-3-yl}propanoic acid (Example A-28);

and a pharmaceutically acceptable salt thereof.

22. The compound according to claim 3 wherein $-R^4-Y-Y^n-$ is $-(CR^{11}R^{12})_n-O-(CR^{11}R^{12})_n-(C=O)-NR^{10}-$ or $-(CR^{11}R^{12})_n-NR^{10}-(C=O)-O-$.

23. The compound according to claim 3 wherein Y is $-(C=O)-$ or $-SO_2-$, Y^n is NR^{10} , and p is 1.

24. The compound according to claim 3 wherein each of R^{11} and R^{12} are independently H and Ar^3 is phenyl.

25. The compound according to claim 3 selected from the group consisting of 2-Methyl-2-{3-[[[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl]amino)methyl]phenoxy}propanoic acid (Example B-5);

2-methyl-2-{3-[[[5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]carbonyl]amino)methyl]phenoxy}propanoic acid (Example B-6);

2-methyl-2-{4-[[[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]carbonyl]amino)methyl]phenoxy}propanoic acid (Example B-7);

2-{3-fluoro-4-[[[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl]amino)methyl]phenoxy}-2-methylpropanoic acid (Example B-9);

2-{3-[[[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl]amino)methyl]phenoxy}butanoic acid (Example B-13);

2-{3-[[[5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]carbonyl]amino)methyl]phenoxy}butanoic acid (Example B-14);

1-{3-[[[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl]amino)methyl]phenoxy}cyclobutanecarboxylic acid (Example B-15);

2-methyl-2-{3-[[[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]amino]carbonyl]oxy)methyl]phenoxy}propanoic acid (Example B-21);


2-ethoxy-3-{3-[[[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]carbonyl]amino)methyl]phenyl}propanoic acid (Example B-23);

2-ethoxy-3-{3-[[[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl]amino)methyl]phenyl}propanoic acid (Example B-24);

and the pharmaceutically acceptable salts thereof.


26. The compound according to claim 4 wherein ring A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

27. The compound according to claim 4 wherein ring A is selected from the group consisting of




wherein — is an optional double bond.

28. The compound according to claim 4 wherein ring A is selected from the group consisting of



wherein — is an optional double bond.

29. The compound according to claim 4 wherein ring A is selected from the group consisting of





wherein — is an optional double bond.

30. The compound according to claim 4 wherein Ar^4 is phenyl, naphthyl, pyridinyl, pyrimidinyl, or pyrazinyl.

31. The compound according to claim 4 selected from the group consisting of

- 1-4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]benzyl)cyclobutanecarboxylic acid (Example C-16);
 1-4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl)cyclobutanecarboxylic acid (Example C-19);
 2-((6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl)methyl)tetrahydrofuran-2-carboxylic acid (Example C-48);
 2-((5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl)methyl)tetrahydrofuran-2-carboxylic acid (Example C-49);
 2-((6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl)methyl)tetrahydro-2H-pyran-2-carboxylic acid (Example C-56);
 2-[(6-[2-[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]pyridin-3-yl)methyl]tetrahydrofuran-2-carboxylic acid (Example C-59);
 2-[(6-[2-[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]pyridin-3-yl)methyl]tetrahydrofuran-2-carboxylic acid (Example C-62);
 2-{5-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyrazin-2-ylmethyl}-tetrahydro-furan-2-carboxylic acid (Example C-77);
 -4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}tetrahydrofuran-2-carboxylic acid (Example C-78);
 2-{6-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-naphthalen-2-ylmethyl}-tetrahydro-furan-2-carboxylic acid (Example C-91);
 and the pharmaceutically acceptable salts thereof.
32. The compound according to claim 5 having a formula:



33. The compound according to claim 31 wherein R⁹ is methyl, ethyl, or benzyl.
 34. The compound according to claim 31 wherein R¹⁷ is H.

35. The compound according to claim 31 selected from the group consisting of
 2-ethoxy-3-{6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-
 yl}propanoic acid (Example D-1);
 2-methoxy-3-(6-{2-[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-
 5 yl]ethoxy}pyridin-3-yl)propanoic acid (Example D-3);
 2-methoxy-3-{6-[2-(4-phenoxyphenyl)ethoxy]pyridin-3-yl}propanoic acid
 (Example D-13);
 2-ethoxy-3-[6-(2-{4-[(phenylsulfonyl)oxy]phenyl}ethoxy)pyridin-3-yl]propanoic
 acid (Example D-17);
 10 2-Ethoxy-3-{5-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-2-yl}-
 propionic acid (Example D-23);
 2-Methoxy-2-methyl-3-{6-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propoxy]-pyridin-
 3-yl}-propionic acid (Example D-27);
 2-Methoxy-2-methyl-3-{5-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-2-
 15 yl}-propionic acid (Example D-29);
 3-(6-{2-[2-(4-Chloro-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-pyridin-3-yl)-2-
 methoxy-2-methyl-propionic acid (Example D-30);
 2-Methoxy-2-methyl-3-{6-[2-(5-methyl-2-phenyl oxazol-4-yl)-ethoxy]-pyridin-3-
 yl}-propionic acid (Example D-35);
 20 2-Methoxy-3-(6-{2-[2-(3-methoxy-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-
 pyridin-3-yl)-2-methyl-propionic acid (Example D-43);
 and the pharmaceutically acceptable salts thereof.
36. A method of treating non-insulin dependent diabetes mellitus in a mammal
 comprising administering to the mammal in need thereof a therapeutically effective amount of
 25 an alpha substituted carboxylic acid compound according to claim 1.
37. The method according to claim 36 wherein said mammal has an impaired
 glucose tolerance.
38. A method of treating polycystic ovarian syndrome in a mammal comprising
 administering to the mammal in need thereof a therapeutically effective amount of an alpha
 30 substituted carboxylic acid compound according to claim 1.
39. A method of treating polycystic obesity in a mammal comprising
 administering to the mammal in need thereof a therapeutically effective amount of an alpha
 substituted carboxylic acid compound according to claim 1.
40. A method of reducing body weight in an obese mammal comprising
 35 administering to the mammal in need thereof a therapeutically effective amount of an alpha
 substituted carboxylic acid compound according to claim 1.

41. A method of treating hyperglycemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 5 42. A method of treating hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
43. A method of treating hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 10 44. A method of treating atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
45. A method of treating hypertriglyceridemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 15 46. A method of treating hyperinsulinemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
47. A method of treating a patient suffering from abnormal insulin and/or evidence of glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to said patient a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 20 48. A method of treating insulin resistance syndrome in humans comprising administering to a patient in need of treatment a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 25 49. A method of treating PPAR-related disorders in humans comprising administering to a patient in need of treatment a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
- 30 50. A method of modulating PPAR activity in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.
51. A method of lowering blood glucose in a mammal, comprising administering to a mammal an amount of an alpha substituted carboxylic acid compound according to claim 1 therapeutically effective to lower blood glucose levels.
- 35 52. A method of modulating fat cell differentiation in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

53. A method of modulating processes mediated by PPAR in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

5 54. A method of increasing insulin sensitivity in mammals, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

55. A method of treating metabolic syndromes selected from the group consisting of galactosemia, maple syrup urine disease, phenylketonuria, hypersarcosinemia, thymine uraciluria, sulfinuria, isovaleric acidemia, saccharopinuria, 4-hydroxybutyric aciduria, glucose-
10 6-phosphate dehydrogenase deficiency, and pyruvate dehydrogenase deficiency comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

56. A composition comprising at least one compound of Formula (I) according to claim 1 and a pharmaceutically acceptable carrier thereof.

15